 |
|
|
|
|
|
General Clinical Research Center
Department of Medicine
Tulane/LSU Medical Center
1430 Tulane Avenue
New Orleans, LA 70112
Grant No. M01 RR05096
URL: http://gcrc.tulane.edu
|
For information
about this GCRC and how to access its resources, please
contact:
Administrative Director
Robert G. Sullivan, M.B.A.
504-585-4000; Fax: 504-585-4045
E-mail: giles@tulane.edu
|
|
|
|
Program Director
Juan J. L. Lertora, M.D., Ph.D.
504-585-4000; Fax: 504-585-4045
E-mail: lerclpha@tulane.edu
Principal Investigator
Paul K. Whelton, M.D.
504-584-2897; Fax: 504-587-7357
E-mail: pwhelton@tulane.edu
Associate Program Director
Mark A. Beilke, M.D.
504-587-7316; Fax: 504-584-3644
E-mail: mabeilke@tulane.edu
Associate Program Director
Steve Nelson, M.D.
504-568-4634; Fax: 504-568-4295
E-mail: snelso1@lsuhsc.edu
|
Research Subject Advocate
Mary Cecile Meyaski-Schluter, R.N., B.S.
504-585-4021; Fax: 504-585-4045
Email: mmeyask@tulane.edu
Nurse Manager
Virginia Garrison, R.N., B.S.N.
504-585-4001; Fax: 504-585-4045
E-mail: vgarris@tulane.edu
Informatics Core Systems Manager
Choots de Gracia, M.P.H.
504-585-4048; Fax: 504-688-6851
E-mail: gcrc@tulane.edu
Biostatistician
Janet M. Hughes, Ph.D.
504-587-7334
E-mail: hughes@tulane.edu
|
|
Special Assays, Services, or Tests
Bombesin
Growth hormone-releasing peptides
Luteinizing hormone-releasing hormone (LH-RH)
LH-RH analogues
Somatostatin
Somatostatin analogues
Vasoactive intestinal polypeptide Special Resources,
Instruments, or Services
Inhalation challenge chamber for challenge testing with
gases and vapors
Reference laboratory for chemical toxicological assays
(HPLC) and assays of peptide hormones and antagonists
Reference laboratory for lymphokine, cytokine, and
interleukin assays
AIDS Immunosuppression: Management algorithm for pediatric subjects
of four-drug combination therapies; dynamics of hepatitis C
infection in subjects with HIV receiving highly active
antiretroviral therapy; neutrophil function in HIV-infected
individuals; pathobiology of bone marrow suppression in AIDS;
mechanisms of resistance to perinatal HIV infection and the role
of host immunologic and viral factors; pharmacokinetic and tolerance
studies of ribavirin in HIV-infected patients; intravenous
gamma-globulin therapy in children with symptomatic HIV infection.
Cardiac Disease: Gender differences in the clinical presentation
of coronary artery disease; antioxidant vitamin levels and coronary
artery disease.
Clinical Immunology and Allergy: Identification of clinically
relevant basidiospore allergens in mold-induced asthma; immunopathogenesis
of shellfish allergy; trial of CD34-selected peripheral blood progenitor
cells with immuno-ablation in the treatment of progressive
multiple sclerosis and severe collagen disease; effects of
parental smoking cessation on asthmatic children; investigational
aminoquinolines in malaria; immunotherapy in mite-sensitive asthma.
Gastroenterology and Hepatic Diseases: Variations in plasma
neurotensin in gastrointestinal disease; plasma membrane alterations
in viral hepatitis B; natural history of Helicobacter-associated
gastritis.
Neuroendocrinology: Evaluation of newly described
growth-hormone-releasing peptide in humans; feasibility
of oral insulin therapy to delay beta cell destruction in
newly diagnosed type 1 diabetes; effects of race and
apolipoprotein and genotype on lipoprotein lipase A activity
and postprandial lipemia; DHEA and success with smoking cessation;
use of peptides (cyclo-[HIS-PRO]) in human circulation and
determination of values in normal and obese subjects under
various conditions.
Oncology: Indium III pentetreotide in somatostatin
receptor-expressing neoplasms; treatment of malignant pleural
mesothelioma with a gene-modified cell line; regional perfusion
of neoplasms: drug infiltration in high-dose regional chemotherapy
for regionally confined melanomas, prophylactic perfusion for
stage I high-risk malignant melanoma, postoperative portal
vein infusion of chemotherapeutic agents in colon adenocarcinoma.
Renal Diseases: Diet, protein, growth, and glomerular
filtration rate in infants with renal disease; growth failure
in children with renal disease; deferoxamine prevention of
toxic oxygen radical-induced renal failure; Intron A plus
ribavirin for treatment of chronic hepatitis; treatment of
HIV infection coinfected with hepatitis C virus using
alpha interferon.
|
 |
|
